Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 with or without Chemotherapy in Stage IV NSCLC
NCT03789604Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- May 2023
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in non-small cell lung cancer (NSCLC), sponsored by CStone Pharmaceuticals. Started Dec 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03789604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789604.